课题基金 / 基金详情

CLINICAL PHARMACOLOGY SHARED RESOURCE

CLINICAL PHARMACOLOGY SHARED RESOURCE
临床药理学共享资源
批准号:
8255518
负责人:
LIONEL David LEWIS
金额:
$14.16万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
关键词:
AliquotAnimalsAntineoplastic AgentsApplications GrantsBackBar CodesBiologicalBiological AssayBiological ProcessBudgetsCYP2C9 geneCYP2D6 geneCalciumCancer CenterCancer Center Support GrantCellsClinicalClinical ChemopreventionClinical OncologyClinical PharmacologyClinical ProtocolsClinical ResearchClinical TrialsComputersConcentration measurementConsultationsDataData AnalysesDatabasesDetectionDevelopmentDocumentationDrug KineticsEnrollmentEpidemiologic StudiesEpidemiologyEtoposideEvaluationEvaluation StudiesFluorescenceFolateFundingFutureGenetic PolymorphismHemoglobinHigh Pressure Liquid ChromatographyIn VitroIndividualInvestigational DrugsKynurenineLaboratory ResearchLeadershipLearningLiquid substanceMailsMalignant NeoplasmsMeasurementMeasuresMethodologyModelingMolecular BiologyMonitorNorris Cotton Cancer CenterNursing ResearchOncology GroupPatient CarePatientsPerformancePeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmaceutical ServicesPharmacistsPharmacodynamicsPharmacogeneticsPharmacogenomicsPharmacology Shared ResourcePharmacotherapyPharmacy facilityPhasePilot ProjectsPlasmaPrintingProcessProtocols documentationReaderResearchResearch DesignResearch PersonnelResource SharingResourcesSalivaSamplingScanningServicesSourceSpecimenSystemTechnologyTestingTherapeutic StudiesTissue SampleTissuesTryptophanTumor TissueUGT1A1 geneUnited States National Institutes of HealthUrineWorkZebraanticancer researchbiobankcostdata modelingdesigndocetaxelin vivomembernoveloncologypre-clinicalpreclinical studyrepositoryresearch studytumorvolunteer

项目摘要

项目成果

LIONEL David LEWIS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary function of the Clinical Pharmacology Shared Resource (CPSR) is to support NCCC investigators in the design, performance, data analysis, and interpretation of clinical pharmacology objectives in preclinical (ex-vivo and in vivo), clinical, chemoprevention, and epidemiological studies, at as low a cost as possible. The CPSR has modified its staffing since the last submission such that it now consists of one clinical pharmacologist, one research assistant and a part of a second research assistant, a research nursing resource, and a part of a research pharmacist. The major CPSR services include: 1) Central processing for biological tissue samples (e.g. cells/tumor tissue/plasma/saliva/urine) and cell samples obtained as part of approved clinical and epidemiological protocols: these services include, but are not limited to, sampleprocessing (including processing peripheral blood mononuclear cells), logging and storage, aliquoting, and mail-outs; 2) (a) Development of novel drug assays (when such assays are not routinely available) using either HPLC (UV/Fluorescence detection) or LC-MS/MS methodology, (b) Performance of drugconcentration measurements in biological fluids and tissues for preclinical and clinical oncology studies; 3) (a) Consultation concerning study design and pharmacokinetic and pharmacodynamic hypothesis-testing in preclinical and clinical studies, (b) Pharmacokinetic and pharmacodynamic data analysis and modeling from pre-clinical and clinical studies; 4) Phase-l and proof-of-principle study research nursing support services; 5) Pharmacogenomic (PGx) assays and expertise applied to cancer drug research; and 6) Research Pharmacy Service for oncology drug research with commercially available and investigational new drugs. The CPSR currently provides 13 NCCC investigators with services valued at $118,881 in chargebacks for FY 2007. NCCC members represent 76% of the total number of investigators using this facility at Dartmouth, and their usage constitutes 87% of total CPSR usage. The total chargebacks for this core were $130,161 during FY2007, and the total operating budget was $397,951, requiring $267,789 in non-chargeback subvention, which is derived from a combination of the NCCC CCSG and chargebacks to other sponsored projects. This shared resource is requesting a budget of $109,722 from the NCCC CCSG for the first year of this competitive renewal (2008-09), representing a level comparable to the current year's support, which will provide 39% of its non-chargeback subvention needs, while the majority of costs are recovered through chargebacks and other institutional support. This core grant budget and the other subvention sources primarily underwrite a portion of the chargeback costs to individual NCCC investigators and provide administrative support for oversight of this shared resource.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
  • 批准号:
    10761171
  • 项目类别:
  • 资助金额:
    $99.92万
  • 财政年份:
    2023
  • 负责人:
    LIONEL David LEWIS
  • 依托单位:
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors
  • 批准号:
    10261525
  • 项目类别:
  • 资助金额:
    $101.56万
  • 财政年份:
    2020
  • 负责人:
    LIONEL David LEWIS
  • 依托单位:
Toxicology, Pathology and Biodistribution Core (TPB Core)
  • 批准号:
    7982610
  • 项目类别:
  • 资助金额:
    $9.59万
  • 财政年份:
    2010
  • 负责人:
    LIONEL David LEWIS
  • 依托单位:
CLINICAL PHARMACOLOGY SHARED RESOURCE
  • 批准号:
    7944619
  • 项目类别:
  • 资助金额:
    $15.14万
  • 财政年份:
    2009
  • 负责人:
    LIONEL David LEWIS
  • 依托单位:
海外基金